Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05611905 · ClinicalTrials.gov registry record
Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid
A clinical trial, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 13
- Enrollment target
NCT05611905: Completed study, sponsored by Johns Hopkins University.
NCT05611905 is a clinical trial that has completed, run by Johns Hopkins University. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05611905 has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The investigators will perform radionuclide PET scans in subjects with infectious diseases to assess whether radio-labeled PABA (11C-PABA) is effective for infection imaging. Tomographic imaging can be used to evaluate disease processes deep within the body, noninvasively and relatively rapidly. The goal is to see if this imaging technique can help differentiate infections from non-infectious processes and also provide information on the causative bacterial class.
Interventions
- DRUG Probenecid
- COMBINATION_PRODUCT 11C-para-aminobenzoic acid PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-12-22 |
| Est. Completion | 2025-11-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05611905
The ClinicalTrials.gov registry entry for NCT05611905 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Probenecid is the first listed.
NCT05611905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05611905 about?
NCT05611905 is a clinical study titled "Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid". The investigators will perform radionuclide PET scans in subjects with infectious diseases to assess whether radio-labeled PABA (11C-PABA) is effective for infection imaging. Tomographic imaging can be used to evaluate disease processes deep within the body, noninvasively and relatively rapidly. Th...
What is the current status of trial NCT05611905?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2023-12-22. Estimated completion is 2025-11-08.
What interventions are being tested in trial NCT05611905?
The interventions under investigation include: Probenecid (DRUG), 11C-para-aminobenzoic acid PET/CT (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05611905?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.